Note: Descriptions are shown in the official language in which they were submitted.
1 332570
METHOD FOR REDUCI~G SKIN IRRITATION
ASSOCIATED WITH DRUG/PENETRATION
ENHANCER COMPOSITIONS
The invention relates generally to reducing skin
irritation in drug/permeation enhancer compositions
formulated for transdermal administration. More
particularly, the invention relates to the use of
glycerin to reduce the skin irritation frequently
associated with permeation enhancer mediated transdermal
; 20 drug delivery. The invention thus encompasses a method
of reducing skin irritation by co-administering various
~ transdermal, enhancer-containing compositions with
'~ glycerin. The invention also extends to compositions for
i transdermal administration which are formulated to
contain glycerin.
The delivery of drugs through skin provides many
advantages; primarily, such a means of delivery is a
comfortable, convenient and non-invasive way of
administering drugs. The variable rates of absorption
and metabolism in oral treatment are avoided, and other
inherent inconveniences -- e.g., gastrointestinal
;~ irritation and the like -- are eliminated as well.
~ Transdermal drug delivery also makes possible a high
,i 35 degree of control over blood concentrations of any
particular drug.
:
. ~
~ 332570
Skin is a structurally complex, relatively thick
membrane. Molecules moving from the environment into and
through intact skin must first penetrate the stratum
corneum and any material on its surface. They must then
penetrate tne viable epidermis, the papillary dermis, and
the capillary walls into the bloodstream or lymph
channels. To be so absorbed, molecules must overcome a
; difEerent resistance to penetration in each type of
tissue. Transport across the skin membrane is thus a
complex phenomenon. However, it is the cells of the
stratum corneum which present the primary barrier to
absorption of topical compositions or transdermally
administered drugs.
To increase skin permeability, and in particular, to
increase the permeability of the stratum corneum (i.e.,
so as to achieve enhanced penetration, through the skin,
of the drug to be transdermally administered), the skin
may be treated with one or more permeation enhancing
agents tor "permeation enhancers", as sometimes referred
to herein) prior to administration of the drug.
Alternatively, and preferably, the drug and permeation
enhance are simultaneously applied or co-delivered.
Various such compounds for enhancing the permeability
of skin are known in the art. U.S. Patent Nos.
.,
4,006,218, 3,551,554 and 3,472,931, for example,
~! respectively describe the use of dimethylsulfoxide
(DMSO), dimethyl formamide (DMF) and N,N-
dimethylacetamide (DM~) to enhance the absorption of
topically applied drugs through the stratum corneum.
Other compounds which have been used to enhance skin
permeability include: decylmethylsu~loxide (CloMSO);
polyethylene glycol monolaurate (PEGML; see e.g., U.S~
Patent ~o. 4,56~,343); the l-substituted azacycloheptan-
2-ones, particularly 1-n-dodecyl-cyclazacycloheptan-2-one
(available under the trademark "Azone" from Nelson
1 33257~
Research & Development Co., Irvine, California, U.S.A.;
see U.S. Patent Nos. 3,989,816, 4,316,893, 4,405,616
and 4,557,934); "cell envelope disordering" compounds
such as methyl laurate or oleic acid in combination with
solvents such as N-2-hydroxyethyl) pyrrolidone (U.S.
Patent No. 4,537,776) or C3 - C4 diols (U.S. Patent
4,552,872, EPA 043738). U.S. Patent 4,593,048 also
discloses a composition stated to promote drug
absorption by the skin, the composition containing a
major amount of a lower alcohol and lesser amounts of
various 6-24C hydrocarbons.
The disadvantage of using many permeation en'nancers
is that they are often quite irritating to the skin.
Attempts to reduce the skin irritation that results from
permeation enhancers have not proven very successful.
The inventors herein have now provided a solution to the
problem, by virtue of having discovered that glycerin is
effective as a topical anti-irritant in reducing skin
irritation from generally mildly to moderately irritating
drug/permeation enhancer combinations. However, the
terms "mildly" and "moderately" are relative terms and
the invention may function equally well in certain
"severely" irritating drug/permeation enhancer
combinations.
Glycerin is well known as an emollient, such as
taught in U.S. Patent 4,687,481, and is used in the
manufacture of cosmetics and soaps. However, applicants
are unaware of any teaching in the art to the effect that
glycerin is an effective anti-irritant when administered
in combination with a wide variety of irritation ~ `
~ producing drug/permeation enhancer compositions. In
- fact, when glycerin is applied to rectal tissues for use
as a laxative in children, it is stated to cause
` dehydration of mucosal tissues to produce an irritant
: ::.', : . , : : : . . - ~:. :: : :
. . - : . ., .: . ~ .: : :~ : : . ' . :`
1 33257G
effect. Physicians Desk Reference, 41st Edition, Medical
Economics Company, Oradel, N.J. 1987, p. 931.
.
The following references provide a general overview
; 5 of anti-irritants: J.P. Guillot et al., Int. Journal of
Cosmetic Sci. 5:255-265 (1983); R. L. Goldemberg,
"Antiirritants" in _rinciples of Cosmetics for the
Dermatologist, Phillip Frost ~ Stephen N. Horwitz, eds.,
London: The C.V. Mosby Company, 1979; R~L. Goldemberg,
J. Soc. Cosmet. Chem. 30:415-427 (Dec. 1979); and U.S.
Patent No. 4,695,456 to Wilder (summarizes theories
relating to the processes involved in chemical irritant
injuryj. The &uillot et al. paper is particularly
: relevant here, as it teaches that glycerin is ineffective
as an anti-irritant (id at p. 263), contrary to
applicants' present discovery.
.~ .
Accordingly, it is a primary object of the present
invention to provide a method for reducing skin
irritation associated with all irritating drug/permeation
enhancer combinations formulated for transdermal
administration for which it is effective, the method
comprising applying glycerin to a selected area of skin
in combination with the selected drug/permeation enhancer
`l 2S composition.
It is still another object of the invention to
provide a composition for transdermal administration of a
selected drug, the composition containing glycerin as an
anti-irritant in addition to drug and permeation
enhancer.
In one aspect of the invention, a method is provided
for reducing the skin irritation associated with
irritating drug/enhancer compositions, the method
comprising applying an effective amount of glycerin to a
predetermined area of skin in combination with the
"~:
1 33257G
selected drug and permeation enhancer. The composition
which is applied may include glycerin in combination
with carriers, vehicles, or the like. The composition
may also contain a mixture of drugs and/or a mixture of
permeation enhancers. While the invention has been found
to be most effective in reducing skin irritation
associated with drug/permeation enhancer formulations
producing mild to moderate skin irritations, it is to be -
recognized that not all subjects react equally to the
same formulation. Hence, what may produce mild
irritation on the skin of one subject might produce
severe irritation on another. Also, the addition of
glycerin might reduce severe irritation on one subject
more than moderate or mild irritation on another.
Therefore, the invention is directed generally to
reducing any grade of skin irritation caused by any
caused drug/permeation enhancer combination for which it
is effective.
:.
By cutaneous "irritation" as used herein is meant a
wide range of adverse skin reactions resulting from
chemical or other irritants. Typically, the adverse skin
reactions are primary skin irritation reactions that
result in localized inflammation or injury. As noted by
Guillot et al., supra, the exact nature of such skin
irritation varies with chemical structure and
concentration of the irritant, duration of contact with
skin, and the rate of penetration of the irritant. m e
immune system is not involved. The various mechanisms
believed to be involved in primary skin irritation are
described in Guillot et al., the disclosure of which is
incorporated herein by reference.
..
"Mildly", "moderately" or "severely" irritating
compositions, while relative terms, are those having an
irritation index as defined under "Experimental", below
and particularly in reference to Table X.
``:
.~
:. ..
7 1 332570
"Penetration enhancement" or "permeation enhancement"
as used herein relates to an increase in the permeability
of skin to a dr~g, i.e., so as to increase the rate at
which the drug permeates through the skin. The enhanced
permeation effected through the use of such enhancers can
be observed, for example, by measuring the rate of
diffusion of drug through animal or human skin using a
diffusion cel~ apparatus. The diffusion cell is
described by Merritt et al. Diffusion Apparatus for Skin
Penetration, J. of Controlled Release, 1 tl984) pp. 161-
162.
By "transdermal" delivery, applicants intend to
include both transdermal (or "percutaneous") and
transmucosal administration, i.e., delivery by actual
passage of a drug through the skin cr mucosal tissue.
By "afflicted situs" is meant a localized area of
pathology, discomfort, infection, inflammation or lesion,
and the immediately surrounding area.
By "application situs" is meant a site suitable for
topical application with or without the means of a
mechanical sustained release device, patch or dressing,
e.g., behind the ear, on the arm, back, chest, stomach,
leg, top of foot, etc.
- "Carriers" or "vehicles" as used herein refer to
carrier materials suitable for transdermal drug
administration, and include any such materials known in
the art, e.g., any liquid, gel, solvent, liquid diluent,
or the like, which is nontoxic and which does not
~ interact with other components of the composition in a
: deleterious manner. Carriers are used to provide the
compositions of the invention in their preferred liquid
form. Examples of suitable carriers for use herein
: include water, mineral oil, silicone, polyethylene
1 332570
glycol, polypropylene glycol, liquid sugars, waxes,
petroleum jelly and a variety of other oils and polymeric
materials.
By the term "pharmacologically active agent" or
"drug" is meant any chemical material or compound
suitable for transdermal or transmucosal administration
which induces a desired biological or pharmacological
effect by topical application to the "affliction situs"
or by systemic delivery from the "application situs" to a
desired target area. Such substances include the broad
classes of compounds normally delivered through body
surfaces and membranes, including skin. In general, this
includes therapeutic agents in all of the major
therapeutic areas including, but not limited to, anti-
infectives such as antibiotics and antiviral agents,
analgesics and analgesic combinations, anorexics,
anthemidines, antiarthritics, antiasthmatic agents,
anticonvulsants, antidepressants, antidiabetic agents,
antidiarrheals, antihistamines, antiinflammatory agents,
antimigraine preparations, antimotion sickness agents,
antinauseants, antineoplastics, antiparkinsonism drugs,
antipruritics, antipsychotics, antipyretics,
antispasmodics, including gastrointestinal and urinary,
; 25 antichloinergics, sympathomimetics, xanthine derivatives,
cardiovascular preparations including calcium channel
blockers, beta-blockers, antiarrhythmics,
antihypertensives, diuretics, vasodilators including
general coronary, peripheral and cerebral, central
nervous system stimulants, cough and cold preparations,
decongestants, diagnostics, hormones (both steroidal and
non-steroidal), hypnotics, immunosuppressives, muscle
relaxants, parasympatholytics, parasympathomimetics,
psychostimulants, sedatives and tranquilizers.
` 35
By "effective" amount of a drug or pharmacologically
active agent is meant a non~oxic but sufficient amount
, .
.~;
. .
;,,~,
,: ,. :; , : .:
1 3J257~
of a compound to provide the desired local or systemic
effect and performance at a reasonable benefit/risk ratio
attending any medical treatment. An "effective" amount
of a permeation enhancer as used herein means an amount
selected so as to provide the desired increase in skin
permeability and, correspondingly, the desired depth of
penetration, rate of administration and amount of drug
delivered. By "effective amount" of an anti-irritant is
meant a quantity sufficient to noticeably reduce
cutaneous irritation as defined above.
In the preferred embodiment of the pres~nt invention,
glycerin is used to reduce the skin irritation associated
with irritating drug/enhancer compositions, typically
irritation resulting from use of common permeation
enhancers such as ethanol, propylene glycol, dimethyl
sulfoxide (DMSO), AzoneTM, the cell envelope disordering
compositions of U.S. Patent Nos. 4,537,776 and 4,552,872,
cited supra, and the like. m e method involves treating
the skin with glycerin prior to or concurrently with
administration of a drug/enhancer composition. The
glycerin may be applied, neat, just prior to the
administration of a drug/enhance composition.
Alternatively, in the preferred embodiment, the
drug/enhancer composition that is to be transdermally
administered is formulated so as to contain an effective
amount of glycerin. The composition may, in addition,
include one or more selected carriers, vehicles, ox
excipients, and various agents and ingredients commonly
employed in dermatological and cosmetic ointments,
lotions or other preparations. For examples, fragrances,
opacifiers, preservatives, anti-oxidants, gelling agents,
perfumes, thickening agents, stabilizers, surfactants,
emollients, coloring agents, and the like may be present.
In the preferred embodiment, i.e., in which a
composition for transdermal administration is formulated
: . : ~:: ::- : ~ : - -
; r
1 332570
1()
to contain an effective amount of glycerin, the
proportions of various drug and enhancer components are
those typically in use. In other words, specific amounts
of drug and/or enhancer are not critical and do not form
part of the invention. The amount of glycerin making up
an "effective amount" is normally in the range of about
0.1 to 70 wt.%, preferably between about 1.0 and 50 wt.%
and most preEerably in the range of about 5 to 20 wt~.
It will be appreciated by those skilled in the art that
the relative amounts of the components in these
compositions can vary a great deal. For example, the
amount of drug present in the composition will depend on
a variety of factors, including the disease or condition
to be treated, the nature and activity of the drug, the
desired effect, possible adverse reactions, the ability
and speed of the drug to reach its intended target, the
cost and availability of the drug, and other factors
within the particular knowledge of the patient and
physician. The amount of enhancer present in the
~; 20 composition will similarly depend on a number of factors,
- e.g., on the depth of cutaneous penetration desired, the
strength of the particular enhancer, and the like.
While the invention is directed to the use of
glycerin in combination with any enhancer composition
there are certain enhancer solvents and cell-envelope
disordering compounds which are preferred. Preferred
cell-envelope disordering compounds are members selected
from the group consisting of methyl laurate, oleic acid,
oleyl alcohol, glycerol monooleate, glycerol dioleate and
alycerol trioleate and mixtures thereof. Preferred
-A; solvents are members selected from the group consisting
~i of a C2 or C3 alcohol, a C3 or C4 diol, DMSO, DMF, DM~,
l-n-dodecyl-cyclazacycloheptan-2-one. N-methyl-
pyrrolidone and N-(2-hydroxyethyl)pyrrolidone and
mixtures thereof.
. 1 :
~`:
~ ~ .
:; r
1 332570
11
The method of delivery of the present compositions
-may also vary, but necessarily involves applying the
selected composition to the skin or other tissue for a
period of time sufficient to provide desired
5 pharmacological or biological response. When applied to
an "afflicted situs" the method may involve direct
application of the composition as an ointment, gel,
cream, lotion, or the like. When applied to an
"application situs" for systemic delivery to another
10 location the method may involve use of a drug delivery
device as taught, for example, in U.S. Patent Nos.
3,742,951, 3,797,494 or 4,568,343. As noted above,
glycerin is preferably co-administered with the
drug/enhancer composition, but can also be used to
15 pretreat the skin, i.e., prior to application of the
transdermal formulation.
Preferred drug delivery devices include a
drug/permeation enhancer reservoir wherein the reservoir
20 contains the drug/enhancer/glycerin combination in liquid
form or gelled or thickened by an agent such as mineral
oil, petroleum jelly and various aqueous gelli;~g agents
and hydrophilic polymers. The reservoir is brought in
- contact with the skin at the application situs and is
25 held in place on the skin using a suitable adhesive as
described, for example, in U.S. Patent No. 4,568,343,
supra and the drug/enhancer/glycerin combination is
applied to the skin through a membrane forming the
reservoir floor which is in contact with the skin. In a
30 preferred embodiment, glycerin is incorporated into the
drug/permeation enhancer reservoir; alternatively, as
above, glycerin may be used instead to pretreat the skin
prior to application of the drug delivery device.
It is to be understood that while the invention has
been described in conjunction with the preferred specific
embodiments thereof, that the foregoing description as
:
. ,.
12 1 332570
well as the examples whicn follow are intended to
illustrate and not limit the scope of the invention.
Other aspects, advantages and modifications within the
scope of the invention will be apparent to those skilled
in the art to which the invention pertains.
Experimental
Preparation of Drug/Enhancer Compositions: Compositions
for respective drug/enhancers are listed in Tables 1-8.
The polar phases (i.e. water, ethanol, glycerin, DMSO,
propylene glycol as listed in respective tables) were
first mixed together with a sufficient quantity of
Carbopol 1342 to provide a 1.0% (w/v) Carbopol content.
Respective drugs were then added to the mixtures at
levels to provide saturation at 32F.(0C.) in final
composition. The mixtures were homogenized with a Virtus
tissue homogenizer at 1000 rpm for 2 minutes. The non-
polar phases (methyl laurate, glycerol monooleate,
glycerol dioleate, oleic acid, etc.) were then added to
the mixtures, when necessary, and emulsified for one
minute at 1000 rpm. Resultant drug/enhancer compositions
were used as is in skin flux and primary skin irritation
studies.
Skin Flux Studies: The in vitro human cadaver skin rates
were measured using non-jacketed permeation cells. The
temperature of the cells was maintained at 32C. by
placing the cells in an aluminum heating block that is
positioned in a stirring-heating module (Pierce Chemical
Company, Rockford, Illinois). The epidermis was
separated from the human cadaver whole skin by the heat-
separation method of Kligman and Christophers (Arch.
Dermatol. 88:702 (1963)) involving exposure of the full
thickness skin to 60 C. heat for 60 seconds, after which
time the epidermis was gently peeled off from the dermis.
The epidermis was placed between the two halves of the
permeation cell with stratum corneum layer facing the
I r~ r~
.. ~.. . . . . . .. . .. ... . .
-
13 1 332570
donor compartrnent. Test formulations were placed on the
stratum corneum. Phosphate buffered saline (PBS)
containing 0.02% sodium azide was placed in the receiver
compartment in contact with the dermal side of the
epidermis. Samples were then withdrawn from the receiver
compartment at predetermined times and analyzed by HPLC.
The drug flux (mg/cm2/hr) across human skin was
calculated from linear regression analysis of the
cumulative amount of drug permeated across skin (mg/cm2)
; versus time (hours).
Primary Skin Irritation: Primary skin irritation was
evaluated for each formulation in 6 albino rabbits. The
back of each animal was shaved 24 hours prior to test
sample application. The gelled test samples were applied
to the backs of the animals using 1 cm2 FinnTM Chambers
containing 0.1 cc of test sample. The entire abdomen of
the animals was then wrapped with surgical tape to
prevent the animals from removing the Finn chambers.
After 24 hours of exposure, the Finn Chambers were
removed from the animals backs. ~ny residual test sample
adhering to the animals' skin was gently removed with
surgical gauze and distilled water. Test sites were
scored for erythema and edema at 1 hour and 48 hours
following removal of the test sample using the scoring
~- scale described in Table X. The irritation index (II)
; was then calculated for each test sample as sum of all
edema and erythema scores in all test animals divided by
the number of animals evaluated (n = 6) and the number of
;` parameters scored (edema + erythema = 2).
.
Example 1
Estradiol composi~ions were formulated using ethanol
~'~ 35 and water as an enhancer system with all but the base
formulation containing glycerin in varying amounts as
indicated in Table I. Flux and irritation indices were
~,
,~
.
. .
14 1 332570
evaluated as described above, and results are set forth
in Table I. All compositions were found to be
substantially non-irritating. It is significant to note
that glycerin had no effect of the flux at glycerin
concentrations ranging from 10 to 40% thereby
demonstrating that glycerin does not function as an
enhancer. It is also significant to note that the flux
of commercially formulated Estraderm was considerably
less than the flux of estradiol formulated with an
enhancer system yet there was some irritation noted with
Estraderm.
TABLE I
Enhancer Composition (% v/v) Flux Irritation
15 Drug EtOH H20 Glycerin ~g/cm /hr Index
Estradiol 60 40 -- 0.86 0
Estradiol 60 30 10 0.93 0
Estradiol 60 20 20 0.84 0
Estradiol 60 -- 40 0.91 0
20 EstradermTM 0.35 0.5
(control)
Estraderm is a tradename of Ciba-Giegy for an
estradiol transdermal system consisting of a patch
housing a gelled alcohol reservoir containing the
estradiol which is transmitted through a rate limiting
membrane in the patch onto the skin to provide nominal in
vivo delivery of 50 micrograms of estradiol per day
through the skin.
Example 2
The effect of glycerin on calcitriol flux and skin
irritation resulting from binary enhancers consisting of
ethanol and methyl laurate was evaluated. The results
are set forth in Table II.
1 332570
Ethanol/water (75/25) produced minimal irritation,
but no skin flux (all experiments were conducted using
100 micrograms/ml calcitriol concentration in all
enhancers). Incorporation of methyl laurate (as a cell-
envelope disordering agent/lipid fluidizer) significantlyincreased calcitriol flux (0.55 ~g/cm2/hr vs. 0) and
also increased irritation (index of 3.5 vs. 0.1).
Incorporation of glycerin (7.5%) reduced the irritation
index (II) from 3.5 to 2.3, a 34% reduction, while not
affecting flux. Lowering the ethanol concentration from
75% to 67.5% further reduced irritation to and index of
1.6 while not reducing flux. These results demonstrate
that glycerin significantly reduces irritation of
moderately irritating percutaneous drug enhancer
compositions, while not decreasing skin flux.
TABLE II
Enhancer Irritation
Composition t% v/v) Methyl Flux Index
20 Drug EtOH H2O Glycerin Laurate ~g/cm /h
:
Calcitriol 75 25 -- -- 0 0.1
Calcitriol 75 21.25 -- 3.75 0.55 3.5
Calcitriol 75 13.75 7.5 3.75 0.50 2.3
25 Calcitriol 67.5 21.75 7.5 3.25 0.55 1.5
Example 3
Estradiol composition containing 40:10
ethanol:glycerol dioleate as a binary enhancer and
varying amounts of glycerin were evaluated with respect
to skin flux and irritation. The results are set forth
in Table III. Ethanol alone (40% in H2O) produced
minimal irritation (II of 0.1) and a flux of 0.39
~g/cm2/hr. Incorporation of the cell-envelope
disorganizer, glycerol dioleate (GDO), approximately
doubled the flux (0.74 ~g/cm2/hr), but also increased
irritation (II of 0.6). Incorporation of glycerin
1 332570
16 `
reduced irritation approximately 50% (II of ~0.3). The
effect of glycerin on irritation was found to be
approximately constant over a wide range of glycerin
concentrations (5 to 30%). Glycerin did not affect flux
at any concentration either by increasing or reducing it.
These data demonstrate that glycerin can reduce the
irritation response of mildly irritating percutaneous
drug/enhancer compositions while not affecting skin flux.
TABLE III
Enhancer Composition (% v/v) Flux Irritation
Drug EtOH H2O Glycerin &DO* ~g/cm2/hr Index
Estradiol 4060 -- -- 0.39 0.1
15 Estradiol 4050 -- 10 0.74 0.6
; Estradiol 4045 5 10 0.66 0.3
Estradiol 4040 10 10 0.69 0.4
Estradiol 4030 20 10 0.68 0.3
: Estradiol 4020 30 10 0.71 0.3
~ 20 EstradermT 0.28 0.7
! (Control)
* Glycerol Dioleate
Example 4
The procedure of Example 3 was repeated using
-" glycerol monooleate (GMO) instead of the dioleate (GDO).
;~ Results are set forth in Table IV. ~t comparable levels,
GMO was significantly more irritating than &DO and
produced a moderately irritating response having an index
;~ of 1.9. Incorporation of 10% glycerin, and reducing the
GMO content accordingly, significantly reduced irritation
.~ by about 58% to an index of 0.8 while not affecting skin
.~ ` flux (0.43 and 0.40 ~g/cm2/hr with and without glycerin).
These data demonstrate that glycerin can reduce the
irritation response of moderately irritating percutaneous
:,
::
;
"" ~, ' "; ""~ ' ''
1 332570
17
drug/enhancer compositions, while not affecting s~in
flux.
TABLE IV
Enhancer Composition ~% v/v) Flux Irritation
Drug EtOH H2O Glycerin GMO* ~g/cm2/hr Index
Estradiol 40 40 -- 20 0.40 1.9
Estradiol 40 40 10 10 0.43 0.8
* Glycerol monooleate
Example 5
The procedure of Example 3 was repeated using a
binary enhancer consisting of 70% propylene glycol and 5%
oleic acid. Results are set forth in Table V. Propylene
glycol/oleic acid alone produced a moderate irritation
index response of 1.4. Incorporation of glycerin in the
place of water (propylene glycol/oleic acid levels
I remaining constant)~ significantly reduced the irritation
¦ index from 1.4 to 0.1, i.e. a 93% decrease, while not
affecting skin flux (1.52 and 1.61 ~g/cm2/hr with and
without glycerin). These results demonstrate that
~ 25 glycerin can reduce the irritation response of moderately
3 irritating percutaneous drug/enhancer compositions, while
not affecting skin flux.
J
TABLE V
3Q Enhancer Composition (% v/v)
Propylene Oleic Flux Irritation
Drug H2O Glycerin Glycol Acid ~g/cm /hr Index
Estradiol 25 -- 70 5 1.61 1.4
35 Estradiol -- 25 70 5 1.52 0.1
`
. ~
1 332570
18
Example 6
Pindolol compositions were formulated using DMSO and
water as indicated in Table VI. The flux and irritation
indices were measured according to the aforementioned
proced~lres. Incorporation of 10% glycerin into the
DMSO/water formulation, and reducing the water content
accordingly, reduced skin the irritation index from 0.5
to 0.3 with corresponding skin flux values of 0.5 and 0.7
~g/cm2/hr. Consistent with previous examples, these
results confirm that glycerin can reduce the skin
irritation response of mildly irritating transdermal
; drug/enhancer compositions, while, again, not adversely
affecting the skin flux.
TABLE VI
- Enhancer Camposition (~ v/v) Flux Irritation
Drug DMSO ~2 Glycerin ~g/cm2/hr Index
.
Pindolol 70 30 -- 0.5 0.5
~`~ 20 Pindolol 70 20 lO 0.7 0.3
,..
.l 25 Example 7
The effect of glycerin on pindolol skin flux and
irritation was evaluated using binary enhancer consisting
of 80% propylene glycol and 20% oleyl alcohol. The 80/20
propylene glycol/oleyl alcohol formulation produced a
high pindolol flux (~25 ~g/cm2/hr) and had a high
irritation index response (6.7). Incorporation of 10%
glycerin, and reducing the oleyl alcohol content
accordingly, had no significant effect on irritation
indices (6.3 v. 6.7) of flux (26.6 v 25.0 ~g/cm2/hr),
demonstrating that glycerin may not affect all
drug/enhancer formulations, particularly when the
irritation index is in the severe range.
,.,~
:~ `
-
1 332570
19
TABLE VII
Enhancer Composition (~ v/v)
Propylene Oleyl Flux Irritation
Drug Glycol Alcohol Glycerin ~g/cm2/hr Index
Pindolol 80 20 -- 25.0 6.7
Pindolol 80 10 10 26.6 6.3
Example 8
The effect of humectants on estradiol skin flux and
irritation was evaluated as follows. Glycerin is a well
known humectant. To evaluate whether the anti-irritant
effect of glycerin is due only to increased hydration of
the skin, a series of humectants were evaluated using a
binary enhancer consisting of 40% ethanol and 10% GDO.
Results are set forth in Table VIII. Estradiol flux
without humectant was determined to be 0.48 ~g/cm2/hr and
the irritation index was 0.6. Incorporation of 20%
glycerin reduced the irritation index by 50% to 0.3 and
had no effect on flux. Two other humectants, propylene
glycol and urea, were also evaluated at the same
concentration as glycerin. Propylene glycol (20~)
increased flux to 0.79 ~g/cm2/hr and increased the
;i 30 irritation index to 0.8. Urea (20% wt/v) reduced flux to
0.21 ~g/cm /hr and increased the irritation index to
1.3. These results demonstrate that the anti-irri~ation
effect of glycerin is a function of more than its
humectant properties.
1 33257G
TABLE VIII
Flux Irritation
Drug Enhancer Composition (~i v/v) ~g/cm /hr Index
S Estradiol 40/50/10 EtOH/H2O/GDo* 0.48 0.6
Estradiol 40/30/20/10 EtOH/H2O/
Glycerin/GDO* 0.42 0.3
Estradiol 40/30/20/10 EtOH/H2O/
Propylene Glycol/GDO* 0.79 0.8
Estradiol 40/30/20/10 EtOH/H2O~
Urea/GDO* 0.21 1.3
Estraderm 0.18 0.7
tControl)
* Glycerol Dioleate
Example 9
The effect of glycerin on irritation resulting from
the use of a drug/enhancer combination using l-n-dodecyl-
cyclazacycloheptan-2-one (Azone) was evaluated as
indicated in Table IX. As may be concluded from that
table, the irritation index of a 55/20/20/5 mixture of
ethanol/H2O/propylene glycol/Azone composition was
reduced from 2.3 to 1.5, i.e. by about 35%, by the
substitution of glycerin for water. Flux of the model
drug compound, estradiol, was not affected significantly.
TABLE IX
Enhancer Composition (% v/v) Flux Irritation
Drug ~g/cm2/hr Index
Estradiol 55/20/20/5 EtOH/H2O/
Propylene Glycol/Azone 1.75 2O30
Estradiol 55/20/20/5 EtOH/Glycerine/
Propylene Glycol/Azone 1.86 1.50
~: .
1 332570
21
TABLE X
Evaluation of Skin Reactions
Value
Erythema and eschar formation:
No erythema 0
Very mild erythema (Barely perceptible~ 1
Mild but well-defined erythema 2
Moderate to severe erythema 3
Severe erythema (beet redness to slight
eschar formation) (injuries in depth) 4
Edema formation:
No edema 0
Very mild edema (barely perceptible)
Mild edema (edges of area well defined
by definite raising) 2
Moderate edema (raised approximately
l millimeter) 3
` Severe edema (raised more than 1 millimeter
and extending beyond the area of
~- 20 exposure) 4
,
The above examples are representative of the many
;`active drugs or therapeutic agents that can be utilized
-25 in the present invention. A listing of a compendium of
drugs would serve no useful purpose as the effectiveness
-`of some may have to be determined empirically. Also, the
enhancer combinations which have been shown are but
illustrative of the many combinations which are within
the scope of the invention. The application of the
present invention to some enhancers may also have to be
empirically determined. In summary, the invention is
directed to any drug/enhancer combination wherein the
addition of glycerin results in a reduction of the skin
irritation index. By following the teachings and
guidelines contained herein one skilled in the art will
be able to readily determine which formulations glycerin
` . .
.~
. .
1 332570
22
may be incorporated into and effectively utilized in
reducing skin irritation without significantly affecting
flux of the active ingredient across the stratum corneum.
. ~ .
` 35
-
.
~ , . . :
